Pharma Mar, S.A.

BME:PHM Lagerbericht

Marktkapitalisierung: €711.9m

Pharma Mar Management

Management Kriterienprüfungen 1/4

Pharma Mar's CEO ist Jose Fernandez Sousa-Faro , ernannt in Jan 1986, hat eine Amtszeit von 38.42 Jahren. besitzt direkt 6.32% der Aktien des Unternehmens, im Wert von €37.57M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 13.3 Jahre bzw. 2 Jahre.

Wichtige Informationen

Jose Fernandez Sousa-Faro

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehaltsn/a
Amtszeit als Geschäftsführer38.5yrs
Eigentum des Geschäftsführers6.3%
Durchschnittliche Amtszeit des Managements13.4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder2.1yrs

Jüngste Management Updates

Recent updates

Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65

Jun 01
Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65

Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry

May 28
Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry

Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 03
Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden

Jan 25
Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden

Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate

Apr 28
Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate

We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability

Mar 08
We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability

Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)

Mar 05
Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)

Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

Feb 09
Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease

Oct 27
We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease

An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued

Sep 27
An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued

Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?

Jul 15
Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?

Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%

May 04
Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%

Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet

Apr 11
Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet

There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding

Mar 16
There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding

Is Pharma Mar (BME:PHM) Using Too Much Debt?

Jan 09
Is Pharma Mar (BME:PHM) Using Too Much Debt?

Pharma Mar (BME:PHM) Seems To Use Debt Quite Sensibly

Sep 08
Pharma Mar (BME:PHM) Seems To Use Debt Quite Sensibly

News Flash: Analysts Just Made A Meaningful Upgrade To Their Pharma Mar, S.A. (BME:PHM) Forecasts

Aug 03
News Flash: Analysts Just Made A Meaningful Upgrade To Their Pharma Mar, S.A. (BME:PHM) Forecasts

Here's Why I Think Pharma Mar (BME:PHM) Is An Interesting Stock

May 31
Here's Why I Think Pharma Mar (BME:PHM) Is An Interesting Stock

Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

May 10
Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

Is Pharma Mar, S.A. (BME:PHM) Expensive For A Reason? A Look At Its Intrinsic Value

Apr 08
Is Pharma Mar, S.A. (BME:PHM) Expensive For A Reason? A Look At Its Intrinsic Value

Announcing: Pharma Mar (BME:PHM) Stock Increased An Energizing 231% In The Last Five Years

Jan 14
Announcing: Pharma Mar (BME:PHM) Stock Increased An Energizing 231% In The Last Five Years

Is Pharma Mar (BME:PHM) A Risky Investment?

Nov 19
Is Pharma Mar (BME:PHM) A Risky Investment?

Geschäftsführer

Jose Fernandez Sousa-Faro

38.5yrs

Amtszeit

€294,000

Vergütung

Mr. José María Fernández Sousa-Faro, Ph D., founded Pharma Mar, S.A.U. in 1986. He Founded Noscira, S.A., in 2000.He serves as the Chief Executive Officer and President of Pharma Mar, S.A.U. He serves as...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Jose Fernandez Sousa-Faro
Founder38.5yrs€294.00k6.32%
€ 45.0m
Pedro Fernandez Puentes
Executive Vice-Chairmanno data€124.00kkeine Daten
Juan Carretero
Founderno datakeine Datenkeine Daten
María de Francia Caballero
Chief Financial Officer24.5yrskeine Datenkeine Daten
José Moreno Martinez-Losa
Head of Capital Markets & Investor Relations9.5yrskeine Datenkeine Daten
Juan Pulido
General Counsel & Secretary of the Board of Directors4.8yrskeine Datenkeine Daten
Sandra Sanchez
Global Compliance Head4.2yrskeine Datenkeine Daten
Lara Vadillo
Communication Directorno datakeine Datenkeine Daten
Belén Veramendi
Director of Corporate Development2.5yrskeine Datenkeine Daten
Luis Cuenca
Director of Human Resources & IT21yrskeine Datenkeine Daten
Luis Mora Capitan
Managing Director of Oncology & Virology Business Units17.3yrskeine Datenkeine Daten
Pascal Besman
Chief Operating Officer of Pharmar U.S.no datakeine Datenkeine Daten

13.4yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: PHMDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (13.3 ).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Jose Fernandez Sousa-Faro
Founderno data€294.00k6.32%
€ 45.0m
Pedro Fernandez Puentes
Executive Vice-Chairmanno data€124.00kkeine Daten
Eduardo Serra Rexach
Independent Other External Director3.5yrs€35.00k0.062%
€ 444.5k
M. Solchaga Catalan
Independent Other External Directorno data€35.00kkeine Daten
Montserrat Andrade Detrell
Proprietary Directorno data€34.00k5.41%
€ 38.5m
Blanca Hernandez Rodriguez
Independent Director5.5yrskeine Datenkeine Daten
Maria Sandra Mera
Representative Proprietary Director3.6yrskeine Datenkeine Daten
Rosa Maria Alonso
Independent Director2.1yrskeine Daten0.0010%
€ 7.4k
Mariano Rodriguez
Independent Coordinating Director2.1yrskeine Datenkeine Daten
Emiliano Aller
Independent Director2.1yrskeine Datenkeine Daten
Fernando Santos
Independent Other External Directorno datakeine Datenkeine Daten
Soledad Miranda
Independent Director1.2yrskeine Datenkeine Daten

2.1yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrener Vorstand: PHMDie Vorstandsmitglieder gelten nicht als erfahren ( 2 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.